

Board Forward Plan

January 2020 Board		
Public		
Regular items:		
Patient Story	G Miflin	
CEOs Report (inc Opt Out, LRP, IBI, Brexit, Gov Review, Operational Model)	B Bassis	
Update on LRP profile on costs (if not in CEO report)	G Methven	
Clinical Governance report	G Miflin	
Board Performance Report	R Bradburn	
Reports from UK Health Depts		
Minutes from Board sub-committees		
Board Forward Plan (for info)		
Other:		
R & D strategy	G Miflin	
ODT strategy (draft document)	A Clarkson	TBC dependent on timescale
Governance & Risk Review	I Bateman	
Diversity & Inclusion strategy (full)	K Robinson/ M Thermidor	
Update on the RESTORE clinical trial of manufactured blood cells	G Miflin	
BAME Taskforce presentation	K Robinson	
Bacterial Screening (following approval of PRF at ET on 30 Oct)	G Methven	
Medical Devices Regulatory Implementation DBC	I Bateman	
Cord Blood Strategy	G Miflin	
Plasma pricing	H Williams	
NCG1 (pricing and service proposals)	H Williams	
Private		
Regular items:		
Brexit Update	I Bateman	
Report from Board Sub-Committee (Finance)		
Review of Board Performance		
Other:		
NHSBT Major Contracts Pipeline (for info)	R Bradburn	
Contracts over £1m and under £3m (for info)		
- ODT Transport Contract		
Stand-alone Seminar (following Board)		
Tbc		

Board Forward Plan

March 2020 Board		
Public		
Regular items:		
Patient Story	A Clarkson	
CEOs Report (inc Opt Out, LRP, IBI, Brexit, Gov Review, Operational Model)	B Bassis	
Clinical Governance report	G Miflin	
Board Performance Report	R Bradburn	
Reports from UK Health Depts		
Minutes from Board sub-committees		
Board Forward Plan (for info)		
Other:		
Project 'Don't Forget the Donors'	A Clarkson	
ODT strategy (sign off on strategy document)	A Clarkson	
Private		
Regular items:		
Brexit Update	I Bateman	
Report from Board Sub-Committee (Finance)		
Review of Board Performance		
Other:		
NHSBT Major Contracts Pipeline (for info)	R Bradburn	
Contracts over £1m and under £3m (for info)		
Stand-alone Seminar (following Board)		
Tbc		

Notes:

Diagnostics Strategy (HW) – deferred indefinitely
 (Stem cell txn strategy (HW) – 2020)

Board seminars following Board meetings: Future Board consider FFP (Laura)